Drugs / Glycine
Glycine
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Maapliv | — | 2025-07-28 | europa.eu ↗ |
| Approved | US (FDA) | GLYCINE 1.5% IN PLASTIC CONTAINER | — | 1976-05-25 | fda.gov ↗ |
Trials 13 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 26 trials | ||||||
| Phase 2 | NCT05799521 | Jun 2023 → Mar 2027 expected | COVID-19 | Indiana University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04738422 | Sep 2020 → Jul 2028 expected | lower respiratory tract disorder | Indiana University | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT00913692 | Jun 2009 → Dec 2011 | herpes labialis | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Phase 2 | NCT00338598 | Jun 2003 → Dec 2015 | alcohol dependence, schizophrenia | Yale University | Completed | No outcome recorded |
| Phase 2 | NCT00268749 | Jul 2002 → Nov 2004 | schizophrenia | Yale University | Completed | No outcome recorded |
| Phase 2 | NCT00005658 | May 2000 → Jan 2002 | schizoaffective disorder, schizophrenia | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT00291226 | Mar 2006 → Jul 2009 | schizophrenia | Yale University | Completed | No outcome recorded |
| Phase 2/3 | NCT00222235 | Jan 2000 → Jun 2004 | schizoaffective disorder, schizophrenia | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT00338221 | Aug 2004 → Apr 2005 | — | University of Virginia | Withdrawn | No outcome recorded |
| Phase 3 | NCT00133562 | Aug 2004 → May 2006 | nutritional disorder | University of Virginia | Withdrawn | No outcome recorded |
| Phase 3 | NCT00000372 | Mar 1998 → Nov 2005 | schizophrenia | Massachusetts General Hospital | Withdrawn | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT06083480 | Dec 2024 → Sep 2028 expected | chronic pain syndrome, osteoarthritis, knee | Vanderbilt University Medical Center | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00405535 | Jun 2004 → Dec 2006 | obsessive-compulsive disorder | Nathan Kline Institute for Psychiatric Research | Completed | No outcome recorded |
Also used as a comparator or background therapy in 4 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT03166228 Comparator | Jan 2018 → Jun 2022 | hypertensive disorder | Assiut University | Completed | No outcome recorded |
| Phase 2 | NCT01720316 Comparator | Dec 2012 → May 2017 | bipolar disorder, schizoaffective disorder | Mclean Hospital | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT07575984 Comparator | Nov 2025 → Apr 2027 expected | ischemic stroke | Pharmasoft | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00635102 Comparator | Oct 1997 → Feb 2008 | alcohol dependence | Yale University | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | glycine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00268749 ↗ |
| Known as | Alkaline glycine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04738422 ↗ |
| Known as | FEMA NO. 3287 | ChEMBL registry synonym — accepted as the source's own label CHEMBL773 ↗ |
| Known as | Glicina | ChEMBL registry synonym — accepted as the source's own label CHEMBL773 ↗ |
| Known as | Glycolixir | ChEMBL registry synonym — accepted as the source's own label CHEMBL773 ↗ |
| Known as | NSC-25936 | ChEMBL registry synonym — accepted as the source's own label CHEMBL773 ↗ |
| Known as | Optate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05799521 ↗ |
| Action | Activate | “the full agonist, glycine, would not be expected to worsen negative symptoms in the presence of clozapine.” NCT00000372 ↗ |
| Modality | Other / unclassified | “the amino acid glycine” NCT00005658 ↗ |
| Route | Oral | “The amino acid glycine, if given orally in adequate dosages” NCT00405535 ↗ |